The neuromuscular junction is built with a large surplus of receptors, so a competitive antagonist can occupy most of them before anything measurable happens. Everything in this module follows from that one fact: why potency and speed of onset run in opposite directions, why a normal twitch does not mean an unblocked patient, why a train-of-four count says something different from a train-of-four ratio, and why one reversal agent has a ceiling and the other does not.
Orientation
What this module covers, and how to work through it
This module covers one line of the MMed syllabus — neuromuscular blocking drugs, monitoring, interactions and reversal — which is one line of syllabus and four sittings of reading. It runs from the receptor outwards: what the drugs bind, how they divide, how each behaves, and how a block is measured and ended.
Lesson 1 settles what the drugs bind and how the class divides. Lesson 2 takes suxamethonium on its own, because a depolarising agonist behaves unlike everything else in the class and its adverse effects follow from that difference. Lesson 3 compares the non-depolarisers, which share a mechanism and differ only in kinetics and side effects. Lesson 4 puts monitoring and reversal together, because in practice they are one decision: you measure the block in order to know which reversal agent can work, and at what dose.
Monitoring comes last rather than second, which is where the standard textbook chapter puts it. Fade cannot be interpreted before you know what a non-depolarising block is, and the post-tetanic count means nothing until you know what receptor occupancy the train-of-four has stopped being able to measure. The patterns make sense once the pharmacology behind them does, and not before.
Prerequisites for the module as a whole
These carry material this module builds on directly and does not repeat. Work through them first if they are not already secure:
- Synaptic transmission: the chemical synapse, with the neuromuscular junction as its worked example. This module assumes you know what happens at the junction without a drug present.
- Stereoselectivity: why cisatracurium is a single isomer of atracurium and what that buys. Named here, explained there.
- Special populations: the pharmacokinetic changes of ageing, which lesson 3 applies to rocuronium — where they alter onset and duration in opposite directions.
Syllabus
MMed syllabus mapping
| Syllabus area | Lessons | What is covered |
|---|---|---|
| Anaesthetic drugs — neuromuscular blocking drugs | 1–3 | Classification by mechanism and by chemical structure; structure–activity; suxamethonium and both phases of block; plasma cholinesterase and its variants; the non-depolarisers compared on onset, duration, metabolism, elimination and cardiovascular effects; Hofmann elimination; dosing and priming |
| Anaesthetic drugs — monitoring, interactions and reversal | 4 | The peripheral nerve stimulator and its five patterns; receptor occupancy; the drug and physiological interactions that alter block; residual block; neostigmine with an antimuscarinic, and sugammadex |
| Clinical Measurement — nerve stimulator modes and interpretation | 4 | The same stimulator, taught once. Lesson 4 carries the Clinical Measurement objective as well, so the equipment and its interpretation cannot come to disagree across two subjects |
Dantrolene and the management of a malignant hyperthermia crisis sit with the miscellaneous drugs objective, not here. Lesson 2 states the trigger relationship and the mechanism at the ryanodine receptor, because a suxamethonium adverse-effect list without them is incomplete, and stops there.
The pathway
All 4 lessons, in order
Part I
The drugs
What they bind, how they are classified, and the two families in turn — the depolariser on its own, then the non-depolarisers compared.
- The junction, classification and structure–activity
What the drugs bind, why one permanently charged nitrogen determines almost everything else about them, and the two classifications that make the rest of the module navigable.
- Suxamethonium: phase I and phase II block, cholinesterase and adverse effects
The only depolarising drug still in use: the two kinds of block it produces, the enzyme that ends its action from outside the junction, and an adverse-effect list that can be reconstructed from the mechanism.
- The non-depolarisers compared: onset, duration, metabolism and elimination
Six drugs that share a mechanism and differ in everything else — onset, duration, metabolism, elimination, cardiovascular effects and dose — and how each property decides a clinical choice.
Part II
Managing the block
Measuring it, the things that change it without anyone intending them to, and ending it.
- Monitoring, interactions, residual block and reversal
Every pattern the peripheral nerve stimulator can deliver and what each one detects, the drugs and physiological states that change the block, and the two ways to end it — with the point at which each fails.
Objectives
The full objective wording
- Classification and structureClassification and structure–activity of the neuromuscular blockers
- SuxamethoniumSuxamethonium: phase I and II block, cholinesterase and adverse effects
- Non-depolarising agentsThe non-depolarisers compared, and Hofmann elimination
- Monitoring and reversalNerve stimulation, interactions, residual block and reversal